1427 ET - WELL Health Technologies is set to continue its acquisitive momentum in 2025, and TD Cowen's David Kwan thinks WELL's unannounced additions could be positive for the balance sheet. In a report, the analyst says that these could account for almost C$75 million in revenue and C$8-C$9 million in Ebitda, which would represent about 6% upside to TD's current forecasts. Kwan says WELL's current M&A pipeline includes 12 letters-of-intent reflecting C$65 million in revenue and in-line Ebitda margins. "With a continued robust M&A pipeline, we believe WELL will remain active with its M&A program that should help it drive strong, profitable growth," Kwan says. Shares are up 1.2% to C$6.70. (adriano.marchese@wsj.com)
(END) Dow Jones Newswires
January 14, 2025 14:27 ET (19:27 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。